How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

594 results for

Androgenic Alopecia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. The association of androgenetic alopecia and insulin resistance is independent of hyperandrogenemia: A case-control study. (PubMed)

The association of androgenetic alopecia and insulin resistance is independent of hyperandrogenemia: A case-control study. Androgenetic alopecia (AGA) occurs due to the effect of androgens and genetic predisposition. The association between hyperandrogenism and insulin resistance (IR) has been clearly documented. In recent years there have been reports supporting the presence of IR in AGA. The study aimed to investigate the presence of IR in women with AGA and discern whether

2015 Australasian Journal of Dermatology

102. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. (PubMed)

A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. Dihydrotestosterone is the main androgen causative of androgenetic alopecia, a psychologically and physically harmful condition warranting medical treatment.We sought to compare the efficacy and safety of dutasteride (type 1 and 2 5-alpha reductase inhibitor) with finasteride (type 2 5-alpha (...) reductase inhibitor) and placebo in men with androgenetic alopecia.Men aged 20 to 50 years with androgenetic alopecia were randomized to receive dutasteride (0.02, 0.1, or 0.5 mg/d), finasteride (1 mg/d), or placebo for 24 weeks. The primary end point was hair count (2.54-cm diameter) at week 24. Other assessments included hair count (1.13-cm diameter) and width, photographic assessments (investigators and panel), change in stage, and health outcomes.In total, 917 men were randomized. Hair count

2014 Journal of American Academy of Dermatology

103. Insulin-Like Growth Factor -1: Roles In Androgenetic Alopecia. (PubMed)

Insulin-Like Growth Factor -1: Roles In Androgenetic Alopecia. Of all the cytokines or growth factors that have been postulated to play a role in hair follicle, insulin-like growth factor-1 (IGF-1) is known to be regulated by androgens. However, how IGF-1 is altered in the balding scalp has not yet been investigated. In this study, expressions of IGF-1 and its binding proteins by dermal papilla (DP) cells obtained from balding versus non-balding hair follicles were quantified using growth

Full Text available with Trip Pro

2014 Experimental Dermatology

104. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. (PubMed)

A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. Dihydrotestosterone is the main androgen causative of androgenetic alopecia, a psychologically and physically harmful condition warranting medical treatment.We sought to compare the efficacy and safety of dutasteride (type 1 and 2 5-alpha reductase inhibitor) with finasteride (type 2 5-alpha (...) reductase inhibitor) and placebo in men with androgenetic alopecia.Men aged 20 to 50 years with androgenetic alopecia were randomized to receive dutasteride (0.02, 0.1, or 0.5 mg/d), finasteride (1 mg/d), or placebo for 24 weeks. The primary end point was hair count (2.54-cm diameter) at week 24. Other assessments included hair count (1.13-cm diameter) and width, photographic assessments (investigators and panel), change in stage, and health outcomes.In total, 917 men were randomized. Hair count

2014 Journal of the American Academy of Dermatology

105. A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02275351 Recruitment Status

2014 Clinical Trials

106. A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia

Andrasfay Therapeutics, Inc. More Information Go to Layout table for additonal information Responsible Party: Intrepid Therapeutics, Inc. ClinicalTrials.gov Identifier: Other Study ID Numbers: 171-7152-201 First Posted: October 31, 2014 Last Update Posted: March 13, 2017 Last Verified: March 2017 Keywords provided by Intrepid Therapeutics, Inc.: androgen alopecia CB-03-01 solution topical Additional relevant MeSH terms: Layout table for MeSH terms Alopecia Alopecia Areata Hypotrichosis Hair Diseases (...) A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail

2014 Clinical Trials

107. A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males

A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved (...) Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our

2014 Clinical Trials

108. Minoxidil Response Testing in Males With Androgenetic Alopecia

Minoxidil Response Testing in Males With Androgenetic Alopecia Minoxidil Response Testing in Males With Androgenetic Alopecia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Minoxidil Response Testing (...) in Males With Androgenetic Alopecia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02198261 Recruitment Status : Completed First Posted : July 23, 2014 Last Update Posted : October 5, 2018 Sponsor: Applied Biology, Inc. Information provided by (Responsible Party): Applied Biology, Inc. Study Details

2014 Clinical Trials

109. Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia

Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02154503 Recruitment Status : Unknown Verified May 2014 by Jerry Shapiro, Vancouver General Hospital. Recruitment status was: Recruiting First Posted : June 3

2014 Clinical Trials

110. Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia (PubMed)

Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia Androgenetic alopecia (AGA) is the most common form of hair loss. Clinically observed hair loss is due to the continuous miniaturization of affected hair follicles. Genetic factors and androgenic factors especially dihydrotestosterone (DHT), which is a testosterone tissue metabolite, play major roles in the pathogenesis of AGA. However, expert opinions about the usefulness of DHT (...) not significant according to the types of alopecia and the control group. Increased serum concentrations of DHT were not correlated with the advance of alopecia.Dihydrotestosterone is the most influential androgen and seems to play a very important role in the pathogenesis of androgenetic alopecia. Based on the results of our study and others, the most important factors would appear to be the genetically-determined sensitivity of the follicles to DHT and their different reactions to androgen concentration.

Full Text available with Trip Pro

2014 Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii

111. Androgenetic Alopecia (Follow-up)

concluded that in Japanese men with androgenetic alopecia, long-term use of oral finasteride maintained progressive hair regrowth without recognized adverse effects. [ ] Other drugs Some drugs are not approved by the FDA but are potentially helpful medications. [ ] In women with androgenetic alopecia, especially those with a component of hyperandrogenism, drugs that act as androgen suppressants or antagonists (eg, spironolactone, oral contraceptives) may be beneficial. Evidence exists of an association (...) . Cases of telogen effluvium often occur in patients with underlying androgenetic alopecia. Therefore, a search for treatable causes of telogen effluvium (eg, anemia, hypothyroidism), especially in patients with an abrupt onset or a rapid progression of their disease, is indicated. Dawson et al, while discussing female androgenetic alopecia, list the following treatment options to arrest hair loss progression and stimulate partial hair regrowth in this disorder: the androgen receptor antagonists

2014 eMedicine.com

112. Traction Alopecia (Overview)

: results of follicular unit test grafting. Dermatol Surg . 2010 Jun. 36(6):959-62. . Rashid RM, Thomas V. Androgenic pattern presentation of scarring and inflammatory alopecia. J Eur Acad Dermatol Venereol . 2010 Jan 6. . Rakowska A, Slowinska M, Kowalska-Oledzka E, Olszewska M, Czuwara J, Rudnicka L. Alopecia areata incognita: true or false?. J Am Acad Dermatol . 2009 Jan. 60(1):162-3. . Abraham LS, Torres FN, Azulay-Abulafia L. Dermoscopic clues to distinguish trichotillomania from patchy alopecia (...) Traction Alopecia (Overview) Scarring Alopecia: Background, Pathophysiology, Epidemiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTA3MzU1OS1vdmVydmlldw== processing > Scarring Alopecia Updated: Feb 26

2014 eMedicine.com

113. Androgenetic Alopecia (Overview)

is noted at times. A mildly increased telogen-to-anagen ratio is often observed. See for more detail. Management The following drugs have been approved by the FDA for the treatment of androgenetic alopecia: Minoxidil: Androgen-independent hair-growth stimulator Finasteride: 5-Alpha reductase type 2 inhibitor The cosmetic results of surgical treatment for androgenetic alopecia are often satisfactory. Micrografting produces a more natural appearance than does the old technique of transplanting plugs. See (...) androgenetic alopecia, while the mean free androgen index was also higher and mean levels of follicle-stimulating hormone were lower. [ ] A study by Polat et al indicated that men with androgenetic alopecia have a higher likelihood of developing urolithiasis than do those with no hair loss, with the risk being 1.3-fold greater in males with vertex-pattern alopecia, and 2.1-fold greater in those with total alopecia. The study included 200 men with urolithiasis and 168 males with no history of renal stones

2014 eMedicine.com

114. Traction Alopecia (Follow-up)

-37; quiz 38-40. . Nusbaum BP, Nusbaum AG. Frontal fibrosing alopecia in a man: results of follicular unit test grafting. Dermatol Surg . 2010 Jun. 36(6):959-62. . Rashid RM, Thomas V. Androgenic pattern presentation of scarring and inflammatory alopecia. J Eur Acad Dermatol Venereol . 2010 Jan 6. . Rakowska A, Slowinska M, Kowalska-Oledzka E, Olszewska M, Czuwara J, Rudnicka L. Alopecia areata incognita: true or false?. J Am Acad Dermatol . 2009 Jan. 60(1):162-3. . Abraham LS, Torres FN, Azulay (...) Traction Alopecia (Follow-up) Scarring Alopecia Treatment & Management: Medical Care, Surgical Care, Consultations Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTA3MzU1OS10cmVhdG1lbnQ= processing > Scarring

2014 eMedicine.com

115. Androgenetic Alopecia (Diagnosis)

is noted at times. A mildly increased telogen-to-anagen ratio is often observed. See for more detail. Management The following drugs have been approved by the FDA for the treatment of androgenetic alopecia: Minoxidil: Androgen-independent hair-growth stimulator Finasteride: 5-Alpha reductase type 2 inhibitor The cosmetic results of surgical treatment for androgenetic alopecia are often satisfactory. Micrografting produces a more natural appearance than does the old technique of transplanting plugs. See (...) androgenetic alopecia, while the mean free androgen index was also higher and mean levels of follicle-stimulating hormone were lower. [ ] A study by Polat et al indicated that men with androgenetic alopecia have a higher likelihood of developing urolithiasis than do those with no hair loss, with the risk being 1.3-fold greater in males with vertex-pattern alopecia, and 2.1-fold greater in those with total alopecia. The study included 200 men with urolithiasis and 168 males with no history of renal stones

2014 eMedicine.com

116. Androgenetic Alopecia (Treatment)

concluded that in Japanese men with androgenetic alopecia, long-term use of oral finasteride maintained progressive hair regrowth without recognized adverse effects. [ ] Other drugs Some drugs are not approved by the FDA but are potentially helpful medications. [ ] In women with androgenetic alopecia, especially those with a component of hyperandrogenism, drugs that act as androgen suppressants or antagonists (eg, spironolactone, oral contraceptives) may be beneficial. Evidence exists of an association (...) . Cases of telogen effluvium often occur in patients with underlying androgenetic alopecia. Therefore, a search for treatable causes of telogen effluvium (eg, anemia, hypothyroidism), especially in patients with an abrupt onset or a rapid progression of their disease, is indicated. Dawson et al, while discussing female androgenetic alopecia, list the following treatment options to arrest hair loss progression and stimulate partial hair regrowth in this disorder: the androgen receptor antagonists

2014 eMedicine.com

117. Traction Alopecia (Treatment)

-37; quiz 38-40. . Nusbaum BP, Nusbaum AG. Frontal fibrosing alopecia in a man: results of follicular unit test grafting. Dermatol Surg . 2010 Jun. 36(6):959-62. . Rashid RM, Thomas V. Androgenic pattern presentation of scarring and inflammatory alopecia. J Eur Acad Dermatol Venereol . 2010 Jan 6. . Rakowska A, Slowinska M, Kowalska-Oledzka E, Olszewska M, Czuwara J, Rudnicka L. Alopecia areata incognita: true or false?. J Am Acad Dermatol . 2009 Jan. 60(1):162-3. . Abraham LS, Torres FN, Azulay (...) Traction Alopecia (Treatment) Scarring Alopecia Treatment & Management: Medical Care, Surgical Care, Consultations Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTA3MzU1OS10cmVhdG1lbnQ= processing > Scarring

2014 eMedicine.com

118. Traction Alopecia (Diagnosis)

: results of follicular unit test grafting. Dermatol Surg . 2010 Jun. 36(6):959-62. . Rashid RM, Thomas V. Androgenic pattern presentation of scarring and inflammatory alopecia. J Eur Acad Dermatol Venereol . 2010 Jan 6. . Rakowska A, Slowinska M, Kowalska-Oledzka E, Olszewska M, Czuwara J, Rudnicka L. Alopecia areata incognita: true or false?. J Am Acad Dermatol . 2009 Jan. 60(1):162-3. . Abraham LS, Torres FN, Azulay-Abulafia L. Dermoscopic clues to distinguish trichotillomania from patchy alopecia (...) Traction Alopecia (Diagnosis) Scarring Alopecia: Background, Pathophysiology, Epidemiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTA3MzU1OS1vdmVydmlldw== processing > Scarring Alopecia Updated: Feb 26

2014 eMedicine.com

119. Androgens, hair loss and eugenics: a tale of discovery and American social history. (PubMed)

Journal Article Portrait Denmark Exp Dermatol 9301549 0906-6705 0 Androgens IM Adult Aged Alopecia history physiopathology Androgens physiology Eugenics history History, 20th Century Hospitals, Psychiatric history Humans Institutionalization history Male Middle Aged Orchiectomy history United States Hamilton James B JB James Hamilton androgenetic alopecia androgens male balding testosterone 2015 03 19 2015 3 27 6 0 2015 3 27 6 0 2016 5 4 6 0 ppublish 25808933 10.1111/exd.12702 (...) Androgens, hair loss and eugenics: a tale of discovery and American social history. 25808933 2016 05 03 2018 12 02 1600-0625 24 6 2015 Jun Experimental dermatology Exp. Dermatol. Androgens, hair loss and eugenics: a tale of discovery and American social history. 412-3 10.1111/exd.12702 Ayob Shanti M SM Dermatology Department, Royal Hallamshire Hospital, Sheffield, UK. Messenger Andrew G AG Dermatology Department, Royal Hallamshire Hospital, Sheffield, UK. eng Biography Historical Article

Full Text available with Trip Pro

2015 Experimental Dermatology

120. Topical Bimatoprost Effect on Androgen Dependent Hair Follicles

Responsible Party: Duke University ClinicalTrials.gov Identifier: Other Study ID Numbers: Pro00017573 First Posted: June 23, 2014 Results First Posted: August 20, 2014 Last Update Posted: September 5, 2014 Last Verified: July 2014 Keywords provided by Duke University: male pattern hair loss androgenetic alopecia bimatoprost Additional relevant MeSH terms: Layout table for MeSH terms Alopecia Alopecia Areata Hypotrichosis Hair Diseases Skin Diseases Pathological Conditions, Anatomical Androgens Bimatoprost (...) Topical Bimatoprost Effect on Androgen Dependent Hair Follicles Topical Bimatoprost Effect on Androgen Dependent Hair Follicles - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Topical Bimatoprost Effect

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>